-
Next generation sequencing workflow with research use only components
from both companies is designed to provide flexibility, time and cost
savings on sample-to-answer solutions
-
Neonatal research applications have been identified as a focus area
-
Laboratory needs can be addressed with turn-key solutions or modular
components
WALTHAM, Mass. and SAN DIEGO, Ca. --
October 16, 2023 -- Revvity, Inc. and
Element Biosciences, Inc., a
developer of the
AVITI™ System, an innovative and emerging genomic sequencing platform, today announced a
collaboration to introduce workflow solutions that save time and effort
required for genomic analysis of samples.
“This collaboration between Revvity and Element Biosciences seeks to
elevate the overall customer experience by providing compelling
application-specific data, stronger support and easier access to the critical
components necessary for a lab to go from sample to result,” said Arvind
Kothandaraman, general manager of multi-omics and specialty diagnostics at
Revvity. “By addressing the typical workflow-related challenges faced by
labs, we are accelerating the democratization of genomic sequencing.”
“Working with Revvity will allow us to greatly expand the reach of
high-quality sequencing as part of a complete solution for the benefit of
customers everywhere,” said Yaron Hakak, SVP of corporate and business
development at Element Biosciences.
Genomic data generated by next generation sequencing (NGS) plays an
increasingly important role in scientific innovation and research. The NGS
process encompasses a series of detailed steps, including sample collection
and processing, nucleic acid extraction, library preparation, quality control,
sequencing, data analysis and integration into laboratory information
management systems. This process can be daunting, especially for labs that are
new to NGS and are considering routine use of genomic sequencing data. This
data is crucial to driving research into human health improvements as
reflected in research publications and ongoing studies in many disease
identification efforts, including neonatal research applications.
Revvity offers carefully curated research use components, spanning the NGS
continuum around the sequencing platform. These offerings include sample
collection devices, a
DBS puncher
for punching dried blood spot samples,
chemagic™ kits
and instruments for automated nucleic acid extraction, a wide range of
liquid handlers
and reagent kits for automated library preparation, the
LabChip® GX Touch HT nucleic acid analyzer
and
VICTOR2™ D
Instrument for sample quality control, and software capabilities that are
vital for data management and interpretation. For labs interested in a service
model,
Revvity Omics, Inc.,
provides end-to-end solutions from delivery of a sample collection kit to
final report, providing the flexibility to access sequence data only or report
only to augment the customer’s in-house capabilities.
When it comes to the NGS platform itself, data quality and flexibility play a
pivotal role in determining a lab’s choice for advancing research. The
Element AVITI System, a flexible benchtop sequencer with industry-leading
performance and cost, delivers high quality, affordable data for any
application, at a range of scale. Element’s AVITI System is quickly
gaining broader adoption, exceeding 100 commercial orders from customers
across the globe. Earlier this year, Element Biosciences announced a new
throughput-based option for its AVITI System that provides the highest quality
sequencing on a benchtop for as low as $200 a genome, or $2 per gigabase.
Revvity Omics has recently adopted Element’s AVITI platform for its
global service business, demonstrating improved technology capabilities,
flexibility and speed.
Revvity and Element Biosciences plan to make the combined solution available
to an expanded customer base interested in the full workflow or specific
modules. Laboratories interested in discussing their research needs can do so
via this
dedicated channel.
About Element Biosciences, Inc.
Element Biosciences is a multi-disciplinary life science company focused on
developing disruptive DNA sequencing technology for research markets. Through
innovating every fundamental element of a sequencing system, Element empowers
customers with affordable, high-quality data and an improved user experience,
which in turn will accelerate scientific discoveries and broaden the use of
genomic research. To learn more about Element, please visit www.elementbiosciences.com
or follow Element on
LinkedIn and
X.
Element Biosciences Media Contact:
Kristi Heim
kristi.heim@elembio.com
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be
done” is a call to action. Revvity provides health science solutions,
technologies, expertise, and services that deliver complete workflows from
discovery to development, and diagnosis to cure. Revvity is revolutionizing
what’s possible in healthcare, with specialized focus areas in
translational multi-omics technologies, biomarker identification, imaging,
prediction, screening, detection and diagnosis, informatics and more.
With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity
serves customers across pharmaceutical and biotech, diagnostic labs, academia,
and governments. It is part of the S&P 500 index and has customers in more
than 190 countries.
Stay updated by following our Newsroom,
LinkedIn,
X,
YouTube, Facebook and
Instagram.
Revvity Media Contact:
Chet Murray
(781) 462-5126
chet.murray@revvity.com